Psychedelics: Drug Development Capabilities

Psychedelics are emerging as a powerful tool for treating a number of mental health conditions, such as depression, post-traumatic stress disorder, substance use disorders, and others. Psychedelics are a subclass of hallucinogenic drugs whose primary effect is to trigger non-ordinary mental states and an apparent expansion of consciousness.

While there is growing interest in tapping into the therapeutic potential of psychedelics, only a handful of companies in the US hold DEA licenses for manufacturing Schedule I of II drug products. Adhering to the strict guidelines for handling and manufacturing Schedule I and II products requires regulatory expertise and years of experience in the space.

Societal has completed key regulatory requirements for moving forward with this work and is now positioned to support customers with the manufacture of high-quality cGMP clinical supplies. Learn how harnessing a CDMO’s extensive knowledge and skills in dealing with controlled substances can help you advance your innovative psychedelic therapeutic safely and efficiently.